The absence of tumor-induced abnormal bone formation in HER2-TTC-treated mice at 500 kBq/kg was also reflected in lower serum levels of the bone formation marker PINP as compared to vehicle control (Figure 4H), and this effect could be observed already on day 28. Here, ERBB2 is linked to neoplasm.